SSRI shows efficacy in reducing menopausal symptoms

Article

Escitalopram, a selective serotonin reuptake inhibitor approved by the US Food and Drug Administration for the treatment of anxiety and depression, significantly reduces the frequency, severity, and bother of hot flashes, according to study findings.

Escitalopram (Lexapro; Forest Laboratories Inc, New York, New York), a selective serotonin reuptake inhibitor approved by the US Food and Drug Administration for the treatment of anxiety and depression, significantly reduces the frequency, severity, and bother of hot flashes, according to the findings of a multicenter, 8-week, randomized, double-blind, placebo-controlled trial.

The trial enrolled 205 women aged 40 through 62 years between July 2009 and June 2010. The women were either in menopause transition (ie, amenorrhea for 60 days or more in the past year) or postmenopausal (ie, 12 months or more since last menses or bilateral oophorectomy).

At baseline, the women experienced a mean of almost 10 hot flashes daily. By week 8, the women taking escitalopram 10 to 20 mg per day experienced a mean reduction in hot flash frequency of 4.6 (95% Confidence Interval [CI], 3.74-5.47) per day versus 3.20 (95% CI, 2.24-4.15) for those taking placebo, for a difference of 1.41 per day (95% CI, 0.13-2.69). More than half (55%) of the treatment group versus 36% of the placebo group reported a decrease of at least 50% in hot flash frequency (P=.009) at 8 weeks.

Similarly at baseline, the mean bother score was 3.14 on a 4-point scale. By week 8, the mean score was 2.48 (95% CI, 2.32-2.64), a 20% decrease, in the treatment group versus 2.76 (95% CI, 2.61-2.91), an 18% decrease, in the placebo group.

Discontinuation because of adverse events was 4% (7 in the active group; 2 in the placebo group). Three weeks after treatment concluded, women in the treatment group reported a mean 1.59 (95% CI, 0.55-2.63; P=.02) more hot flashes daily than women in the placebo group.

Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women. JAMA. 2011;305(3):267-274.

Recent Videos
First US national HPV conference highlights advances in cancer prevention | Image Credit: uchealth.com.
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
1 expert is featured in this series.
Susanna Mitro, PhD, reveals ethnic disparities in uterine fibroid diagnosis | Image Credit: divisionofresearch.kaiserpermanente.org.
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Jihong Liu, ScD, explains how to improve perinatal outcomes in COVID patients | Image Credit: sc.edu.
1 expert is featured in this series.
Jihong Liu, ScD, highlights adverse perinatal outcomes linked to the COVID pandemic | Image Credit: sc.edu.
Experts highlight infant health benefits from minor diet changes in pregnancy | Image Credit: ohsu.edu.
Connie Stark, RNC, PNC, provides fertility preservation insights for endometriosis patients | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.